Skip to main content
SpringerLink
Log in

Exendin 4

AC 2993, AC 2993 LAR

  • Adis R&D Profile
  • Published:
BioDrugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Notes

  1. This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

References

  1. Parkes DG, Young AA, Petrella E, et al. Pharmacokinetics of exendin-4 in the rat following intravenous, subcutaneous and intraperitoneal administration. 81st Annual Meeting Endocrine Society; 1999 Jun 12; San Diego, 216-7

  2. Kolterman O, Young G, Parker J, et al. Stimulation of endogenous insulin secretion by subcutaneous AC2993 (synthetic exendin-4) in healthy overnight fasted volunteers. Diabetes 1999 May; 48Suppl. 1: 199

    Google Scholar 

  3. Amylin Pharmaceuticals Inc. Amylin Pharmaceuticals reports successful study of second diabetes drug candidate AC2993 (synthetic exendin-4) in type 2 diabetes [media release 1999 Apr 30]. Available from URL: http://www.amylin.com [Accessed 2002 Jul 2]

  4. Eng J, Friedrich I. Exendin family — agonist and antagonist of GLP-1 receptor. 15th International Diabetes Federation Congress; 1994 Nov 6–11; Kobe, 22

  5. Gedulin R, Jodka C, Hoyt JA, et al. Exendin-4 decreases hemoglobin A(1c) in diabetic fatty Zucker rats. Diabetes 1998 May; 47Suppl. 1: 280

    Google Scholar 

  6. Edwards CMB, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose in healthy volunteers. Diabetic Med 2000 Mar; 17Suppl. 1: 69

    Google Scholar 

  7. Amylin Pharmaceuticals Inc. Amylin Pharmaceuticals reports positive phase 2 study of AC2993 (synthetic exendin-4) in people with type 2 diabetes [media release 1999 Oct 28]. Available from URL: http://www.amylin.com [Accessed 2002 Jul 2]

  8. Amylin Pharmaceuticals Inc. Amylin Pharmaceuticals announces results from a new dose-finding phase 2 study of AC2993 (synthetic exendin-4) [media release 2000 Jan 7]. Available from URL: http://www.amylin.com [Accessed 2002 Jul 2]

  9. Amylin Pharmaceuticals Inc. Amylin Pharmaceuticals announces cardiovascular risk factor reduced by AC2993 (synthetic exendin-4) [media release2000 Jan 10]. Available from URL: http://www.amylin.com [Accessed 2002 Jul 2]

  10. Maksoud H, Barrow BA, Manley SE, et al. Subcutanous exendin-4 improves 24 hour glucose exposure in type 2 diabetes. Diabetes Res Clin Pract 2000 Sep; 50Suppl. 1:40

    Google Scholar 

  11. Bhavsar SP, Watkins JJ, Young AA. Central and peripheral administration of exendin-4 reduces food intake in rats. Diabetologia 1998 Aug;41Suppl. 1: 214

    Google Scholar 

  12. Brynes AE, Edwards CMB, Stanley SA, et al. Exendin-4 reduces energy intake at a free choice buffet meal in healthy volunteers. Diabetic Med 2000 Mar; 17Suppl. 1: 69

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Exendin 4. BioDrugs 16, 220–222 (2002). https://doi.org/10.2165/00063030-200216030-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200216030-00008

Search

Navigation